Pixel Watch 4 pricing leak could mean good news for those fearing a hike
Unless there are any tariff impacts, this suggests US prices may also remain flat, starting at $349.
With the upgrades to the specs of the Google wearable looking modest, it would be logical that there would be little to no price hike.
It's not too long now until we meet the Pixel Watch 4. While we've managed to get some insight into the specs and colors of the next Google wearable, one aspect remained a mystery. However, we now have our best insight yet into how much it might cost.
According to a report from Dealabs, Google will keep the Pixel Watch 4 pricing unchanged in France and the wider European market. The smaller 41mm model will be priced at €399 for Wi-Fi and €499 for LTE, while the larger 45mm versions will come in at €449 and €549, respectively.
If those prices are accurate, US buyers may also be spared a price hike this year. The Pixel Watch 3 launched at $349 for the 41mm Wi-Fi model, $399 for the 41mm LTE, $399 for the 45mm Wi-Fi, and $449 for the 45mm LTE. Google may stick with the same pricing tiers for the Pixel Watch 4.
Given how modest the hardware changes are this year, a flat price seems logical. The Pixel Watch 4 is expected to reuse the same Snapdragon W5 Gen 1 chip as its predecessors, albeit with slightly larger batteries and a new co-processor to help with AI tasks. Other potential upgrades include faster charging, a more repairable design, and new emergency features like Breathing Emergencies alerts and satellite communication support.
One unknown is whether the Trump administration's shifting tariff policies could impact US pricing. Some of Google's hardware is still assembled in China, and new trade measures could introduce added costs. That said, any such impact remains speculative at this stage.
Google is set to reveal the Pixel Watch 4 officially at its Made by Google event on August 20. Pre-orders are expected to open on the same day, so we only have a month to wait for price confirmation.
Got a tip? Talk to us! Email our staff at
Email our staff at news@androidauthority.com . You can stay anonymous or get credit for the info, it's your choice.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
Supernus Pharmaceuticals, Inc. ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the second quarter 2025 financial and business results on Tuesday, August 5, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will be open for questions. A live webcast will be accessible in the Events & Presentations section of the Company's Investor Relations website at Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time. Following the live call, a replay will be available on the Company's Investor Relations website at The webcast will be available on the Company's website for 60 days following the live call. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. For more information, please visit Forward-Looking Statements This press release includes forward-looking statements. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the proposed acquisition of Sage by Supernus may not be completed; the possibility that competing offers or acquisition proposals for Sage will be made; the delay or failure of the tender offer conditions to be satisfied (or waived), including insufficient shares of Sage common stock being tendered in the tender offer; the failure (or delay) to receive the required regulatory approvals of the proposed acquisition; the possibility that prior to the completion of the transactions contemplated by the acquisition agreement, Supernus' or the Sage's business may experience significant disruptions due to transaction related uncertainty; the effects of disruption from the transactions of Sage's business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufactures, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the failure of the closing conditions set forth in the acquisition agreement to be satisfied or waived; Supernus' ability to sustain and increase its profitability; Supernus' ability to raise sufficient capital to fully implement its corporate strategy; the implementation of Supernus' corporate strategy; Supernus' future financial performance and projected expenditures; Supernus' ability to increase the number of prescriptions written for each of its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; Supernus' ability to increase its net revenue from its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; Supernus' ability to commercialize its products including Qelbree; Supernus' ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; Supernus' product research and development activities, including the timing and progress of Supernus' clinical trials, and projected expenditures; Supernus' ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize Supernus' product candidates; Supernus' ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; Supernus' expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus' product candidates; the accuracy of Supernus' estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus' ability to increase its manufacturing capabilities for its products and product candidates; Supernus' projected markets and growth in markets; Supernus' product formulations and patient needs and potential funding sources; Supernus' staffing needs; and other risk factors set forth from time to time in Supernus' filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
Yahoo
28 minutes ago
- Yahoo
ETFGI: Active ETFs Hit Record $1.5T in Assets
Global actively managed exchange-traded funds climbed to a record $1.5 trillion in assets during June, powered by $46.8 billion in monthly inflows that pushed year-to-date flows to an unprecedented $267 billion, according to ETFGI data released Tuesday. The milestone represents a 26.7% jump in assets from $1.2 trillion at the end of 2024, according to ETFGI's June 2025 Active ETF and ETP industry landscape insights report. The active ETF surge reflects investor appetite for professional management as markets navigate economic uncertainty, with the industry posting 63 months of consecutive net inflows. Assets in actively managed ETFs have grown from $1.4 trillion in May to the new June record, with the category now representing a larger share of the broader ETF ecosystem, according to the report. The industry spans 3,805 actively managed ETFs from 573 providers listed on 42 exchanges across 33 countries. Equity-focused active ETFs gathered $24.7 billion in net inflows during June, bringing year-to-date inflows to $149 billion, higher than the $89.4 billion recorded through the same period in 2024, according to ETFGI. Fixed-income active ETFs reported $20.5 billion in June inflows, pushing year-to-date flows to $102.6 billion compared to $54.5 billion in 2024. JMTG Leads as Active ETF Momentum Grows The top 20 active ETFs by net new assets collectively gathered $19.7 billion during June, according to the report. The JPMorgan Mortgage-Backed Securities ETF (JMTG) led with $5.8 billion in inflows, followed by the JPMorgan Active High Yield ETF (JPHY) at just under $2 billion and the Direxion Daily TSLA Bull 2X Shares (TSLL) with $1.1 billion. JPMorgan products dominated the top inflow rankings, with the JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) gathering $877.6 million and the JPMorgan Ultra-Short Income ETF (JPST) adding $752 million during the month, according to ETFGI data. Top 10 Actively Managed ETFs by Net New Assets June 2025 Fund Assets Under Management Year-to-Date Flows June Flows JPMorgan Mortgage-Backed Securities ETF (JMTG) $5.8B $5.8B $5.8B JPMorgan Active High Yield ETF (JPHY) $2B $2B $2B Direxion Daily TSLA Bull 2X Shares (TSLL) $6.2B $4B $1.1B YieldMax MSTR Option Income Strategy ETF (MSTY) $5.2B $4B $897.2M JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) $28.1B $7.9B $877.6M Janus Henderson AAA CLO ETF (JAAA) $21.8B $5.2B $876.5M Capital Group Dividend Value ETF (CGDV) $18.6B $4.5B $835.9M iShares U.S. Equity Factor Rotation Active ETF (DYNF) $19.2B $4.4B $784.4M Neos Nasdaq-100 High Income ETF (QQQI) $2.6B $1.8B $779.4M JPMorgan Ultra-Short Income ETF (JPST) $31.9B $3.7B $752M Source: & ETFGI Data Market performance supported the flows, with the S&P 500 rising 5.1% in June to bring first-half 2025 gains to 6.2%, according to Deborah Fuhr, managing partner, founder and owner of ETFGI. Developed markets outside the U.S. increased 3.2% in June and gained 20.3% year to date, while emerging markets rose 4.8% for the month with 11.4% year-to-date returns. The record-breaking year-to-date inflows of $267 billion surpassed the previous annual records of $153.5 billion in 2024 and $80 billion in 2021, according to the report. The sustained momentum reflects growing investor confidence in active management strategies within the ETF | © Copyright 2025 All rights reserved Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Astrana Health, Inc. Schedules 2025 Second Quarter Financial Results Release and Conference Call
ALHAMBRA, Calif., July 22, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the second quarter ended June 30, 2025, after the close of the stock market on Thursday, August 7, 2025. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day. Astrana Health Logo (PRNewsfoto/Astrana Health, Inc.) Participant Dial-in Numbers: 877-858-9810 / +1 201-689-8517 To access the call, please dial in approximately five minutes before start time. An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website ( after issuance of the earnings release. Webcast The call will also be available via online webcast at: Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call. About Astrana Health, Inc. Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system. Today, Astrana supports more than 20,000 providers and over 1.6 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit FOR MORE INFORMATION, PLEASE CONTACT: Grant Hesser, Investor Relations Cision View original content to download multimedia: SOURCE Astrana Health, Inc.
